Test whether fluoxetine retains cognitive-flexibility / WM / attention phenotype under Slc6a4 LOF or SERT-matched blockade that abolishes SERT-class attribution

Fluoxetine cognitive-flexibility / WM / attention phenotypes are often framed as SERT orthosteric blockade, yet Bengel is a Slc6a4/SERT KO tool, Holmes 2003 is a SERT-null anxiety phenotype, Brigman is a separate-arm cogn phenocopy / necessity-leaning prior (fluoxetine-WT OR 5-HTT-null improve reversal; no fluoxetine-in-SERT-KO arm — honesty NOT residual-positive; often AGAINST residual), and Nikiforuk is a fluoxetine set-shifting phenotype — none score residual-positive under SERT abolish. This discussion asks whether any residual fluoxetine cognitive-flexibility / WM / attention phenotype survives a Slc6a4 LOF or SERT-matched blockade that abolishes SERT-class attribution on the same panel.

Claim

On a pre-registered acute/subacute rodent (Bengel/Brigman/Nikiforuk-class or Gamo-class) cognitive-flexibility / WM / attention panel with a fluoxetine-alone arm, a SERT genetic LOF (Slc6a4) or SERT-matched blockade that abolishes SERT-class attribution, and a fluoxetine-under-abolish arm: under the same condition that abolishes SERT-class attribution, fluoxetine retains residual cognitive-flexibility / WM / attention phenotype ≥50% of fluoxetine-alone (cognitive-flexibility / WM / attention units as pre-specified; α/N pre-specified) — assumption-kill / sert-insufficiency.

Why it matters

Fluoxetine cognitive-flexibility / WM / attention phenotypes are often framed as SERT orthosteric blockade; Bengel is a Slc6a4/SERT KO tool prior, Holmes 2003 is a SERT-null anxiety phenotype prior, Brigman is a separate-arm cogn phenocopy / necessity-leaning prior (fluoxetine-WT OR 5-HTT-null improve reversal; no fluoxetine-in-SERT-KO arm — honesty NOT residual-positive; often AGAINST residual), and Nikiforuk is a fluoxetine set-shifting phenotype prior — none score residual-positive under SERT abolish. N26 asks whether residual fluoxetine cognitive-flexibility / WM / attention phenotype survives a Slc6a4 LOF or SERT-matched blockade that kills SERT-class attribution — sert-insufficiency assumption-kill. Especially distinct from N25 (atomoxetine residual under NET genetic LOF / NET-matched block — SERT ≠ NET; fluoxetine ≠ atomoxetine); N15 (modafinil residual under DAT-matched block — DAT ≠ SERT); N22 (tyrosine residual under AMPT — AMPT ≠ SERT LOF); N23 (guanfacine residual under α2A LOF / α2-antagonist — α2 ≠ SERT); N24 (caffeine residual under Adora2a/A2A abolish — A2A ≠ SERT); also N16–N21 ≠ N26; N2 holds sole ip_class=none; NOT MB/MAOI. Soft-claims: discussion — matched residual-fluoxetine under SERT abolish that abolishes SERT-class attribution H2H UNKNOWN; cogn-panel genetic necessity-abolish H2H UNKNOWN; PRIOR_ART PARTIAL (necessity-leaning phenocopy FOUND; residual-positive under abolish absent; phenotype/tool priors FOUND); soft-complete empty ≠ novelty / ≠ failure; N1–N25 ≠ proof.

Mechanism sketch

Sert-insufficiency assumption-kill: fluoxetine moves cognitive-flexibility / WM / attention phenotypes and is framed as selective SERT blockade, with Slc6a4/SERT KO as a genetic tool (Bengel) and published flexibility/anxiety phenotype priors (Brigman reversal phenocopy; Nikiforuk set-shifting; Holmes 2003 anxiety); no published head-to-head scores residual-positive fluoxetine cognitive-flexibility / WM / attention under a Slc6a4 LOF or SERT-matched blockade that abolishes SERT-class attribution on the same panel as a retained residual. Prefer cell/slice/block-QC before new animal where a named published abolish-verification system can lock residual first (or as cheap parallel); in vivo Bengel/Brigman/Nikiforuk-class or Gamo-class rodent cognitive-flexibility / WM / attention panel remains the primary kill path. Brigman 20032063 is phenocopy / necessity-leaning (separate arms: fluoxetine-treated WT vs vehicle; 5-HTT null vs WT) — do NOT misread as residual-positive; often AGAINST residual-under-SERT-LOF. Holmes 12464448 (promoted; OUT of public prior_art) is antidepressant TST necessity (fluoxetine anti-immobility abolished in 5-HTT−/−) — AGAINST residual for that endpoint; not cogn residual H2H. KO-tool prior (Bengel 9547354), anxiety phenotype (Holmes 14653308), and set-shifting phenotype (Nikiforuk 20580164) lack residual-under-SERT-abolish cogn arms — PRIOR_ART PARTIAL; do not invent residual-positive H2H; do not invent cogn-panel genetic necessity-abolish H2H; do not treat Brigman as residual-positive; do not treat Holmes TST abolish as cogn residual; do not collapse to N25 NET. Competing caveats: abolish condition fails to kill SERT-class attribution / fluoxetine-alone null / underpowered strata / assay-identity mismatch (phenotype ≠ residual; phenocopy ≠ residual-under-abolish; antidepressant TST ≠ cogn panel; DAT-KO ≠ SERT LOF; NET ≠ SERT) leave the test inconclusive rather than refuted; soft-complete empty ≠ novelty / ≠ residual-gain proof; N15 ≠ this (DAT ≠ SERT); N16 ≠ this; N17 ≠ this; N18 ≠ this; N19 ≠ this; N20 ≠ this; N21 ≠ this; N22 ≠ this (AMPT ≠ SERT LOF); N23 ≠ this (α2 ≠ SERT); N24 ≠ this; N25 ≠ this (SERT ≠ NET; fluoxetine ≠ atomoxetine). NOT MB/MAOI (SERIES_FROZEN).

Prior art

• PMID 9547354 / DOI 10.1124/mol.53.4.649 — Bengel: serotonin-transporter-deficient mice — high-affinity [³H]5-HT uptake absent in 5-HTT−/−; MDMA locomotor effect abolished (Mol Pharmacol 1998) — KO tool prior; no fluoxetine cogn residual-under-abolish arm. doi.org HEAD 302 (PubMed DOI verified).
• PMID 14653308 / DOI 10.1046/j.1601-1848.2003.00050.x — Holmes: SERT-null mutant anxiety-related behavior (background-dependent) (Genes Brain Behav 2003) — KO anxiety phenotype prior; no fluoxetine cogn residual arm. doi.org HEAD 302 (PubMed DOI verified).
• PMID 20032063 / DOI 10.1093/cercor/bhp266 — Brigman: pharmacological (chronic fluoxetine in C57BL/6J) OR genetic (5-HTT null) SERT inactivation improves reversal learning (Cereb Cortex 2010) — cogn phenocopy / necessity-leaning; arms tested separately; NO fluoxetine-in-SERT-KO residual arm; honesty NOT residual-positive; often AGAINST residual. doi.org HEAD 302 (PMC2912649).
• PMID 20580164 / DOI 10.1016/j.psyneuen.2010.06.001 — Nikiforuk: antidepressants incl. fluoxetine alleviate stress-induced ED set-shifting deficit; also promote flexibility in unstressed rats (Psychoneuroendocrinology 2011) — fluoxetine cognitive-flexibility phenotype prior; no SERT-abolish residual arm. doi.org HEAD 302 (PubMed DOI verified).

Baseline claimed

Under SERT genetic LOF (Slc6a4) or SERT-matched blockade that abolishes SERT-class attribution, fluoxetine still retains cognitive-flexibility / WM / attention phenotype on the same panel — or Brigman 20032063 already proves residual fluoxetine under SERT abolish — or Bengel SERT KO / Holmes 2003 anxiety / Nikiforuk set-shifting already constitute residual-under-abolish or cogn-panel genetic necessity-abolish H2H — or Holmes 12464448 TST abolish already is cogn residual — or N15 modafinil-DAT / N16 plasma-Cr/PCr / N17 Hericium-NGF/TrkA / N18 theanine-adenosine / N19 Rhodiola-HPA / N20 Bacopa-AChE / N21 nicotine-nAChR / N22 tyrosine-AMPT / N23 guanfacine-alpha2 / N24 caffeine-A2A / N25 atomoxetine-NET / N1–N25 already settle residual fluoxetine under SERT abolish.

Baseline measured

Bengel Slc6a4/SERT KO tool LITERATURE without fluoxetine cogn residual arm (PMID 9547354). Holmes SERT-null anxiety LITERATURE phenotype prior without fluoxetine cogn residual arm (PMID 14653308). Brigman fluoxetine OR 5-HTT null improve reversal LITERATURE cogn phenocopy / necessity-leaning; separate arms; NO fluoxetine-in-SERT-KO residual arm; honesty NOT residual-positive; often AGAINST residual (PMID 20032063). Nikiforuk fluoxetine set-shifting LITERATURE phenotype prior without SERT-abolish residual arm (PMID 20580164). Holmes 12464448 fluoxetine TST anti-immobility abolished in 5-HTT−/− LITERATURE promoted antidepressant necessity AGAINST residual for that endpoint; not cogn residual H2H (OUT of public prior_art; baseline_measured/mechanism OK). Matched residual-positive fluoxetine under Slc6a4 LOF or SERT-matched block that abolishes SERT-class attribution UNKNOWN (soft-complete Q_resid_tight NON-MATCH residual-positive; Q_brigman_arms confirms no fluox×KO residual arm; cogn-panel genetic necessity-abolish H2H NOT FOUND). Residual fluoxetine phenotype ≥50% of fluoxetine-alone when SERT-class attribution abolished PREDICTION. N15 ≠ N26 (DAT ≠ SERT); N16 ≠ N26; N17 ≠ N26; N18 ≠ N26; N19 ≠ N26; N20 ≠ N26; N21 ≠ N26; N22 ≠ N26 (AMPT ≠ SERT LOF); N23 ≠ N26 (α2 ≠ SERT); N24 ≠ N26; N25 ≠ N26 (SERT ≠ NET; fluoxetine ≠ atomoxetine); N1–N25 ≠ proof — soft-complete empty ≠ novelty / ≠ residual-gain proof; do not invent residual; do not treat Brigman as residual-positive; do not treat Holmes TST as cogn residual; do not invent necessity kill.

Actionable limitations

1. Do not treat N1–N25 as proving N26 — especially N25 ≠ N26 (SERT ≠ NET; fluoxetine ≠ atomoxetine); N15 ≠ N26 (DAT ≠ SERT); N22 ≠ N26 (AMPT ≠ SERT LOF); N23 ≠ N26 (α2 ≠ SERT); N24 ≠ N26 (A2A ≠ SERT); N16 is plasma-Cr↑ without ³¹P PCr fails SD WM; N17 is Hericium residual under NGF/TrkA block; N18 is L-theanine residual under caffeine-matched adenosine; N19 is Rhodiola residual under HPA/cortisol-matched; N20 is Bacopa residual under donepezil/AChE occupancy match; N21 is nicotine residual under mecamylamine/nAChR block; soft-complete empty ≠ demonstrated residual gain.
2. Necessity-leaning phenocopy FOUND — Brigman 20032063 constrains SERT bridge (separate-arm phenocopy; often AGAINST residual) — PRIOR_ART PARTIAL OK, not auto-REJECT; do not invent residual-positive H2H; do not treat Brigman as residual-positive; do not treat Holmes 12464448 TST abolish as cogn residual; do not invent cogn-panel genetic necessity-abolish H2H (soft-complete empty). Phenotype/tool ≠ residual — Bengel 9547354 KO tool; Holmes 14653308 anxiety; Nikiforuk 20580164 set-shifting lack residual-under-SERT-abolish arms.
3. Prefer cell/slice/block-QC before new animal; lock same-panel acute/subacute rodent (Bengel/Brigman/Nikiforuk-class or Gamo-class) cognitive-flexibility / WM / attention with fluoxetine ± Slc6a4 LOF or SERT-matched challenge as primary kill path; no dosing; NOT MB/MAOI; not N15–N25 clones; orthosteric_drift=false; do not burn ip_class=none; do not collapse to N25 NET.

Method

propose-assay

Labels

status_labels: [NEGATIVE] novelty_tag: assumption-kill polarity: negative openlabs_target: discussion openlabs_topic: neuroscience-brain tags: nootropics, brain-longevity risk_class: research-discussion

Prediction variables

Ablate

• remove same-panel contrast of residual fluoxetine cognitive-flexibility / WM / attention phenotype under Slc6a4 LOF or SERT-matched blockade that abolishes SERT-class attribution: Without the abolish×residual H2H on a Bengel/Brigman/Nikiforuk-class or Gamo-class panel with a fluoxetine arm, separate phenocopy/necessity-leaning LITERATURE and phenotype/tool LITERATURE cannot show sert-insufficiency as a residual-positive kill.
• remove verified abolish gate (Slc6a4 LOF or SERT-matched blockade that abolishes SERT-class attribution) plus fluoxetine-alone comparator as the residual gate: Without verified SERT-class abolish and fluoxetine-alone comparator under the same condition, residual fluoxetine is just “another monoamine agent under nonspecific challenge,” not an assumption-kill of SERT-class sufficiency for the fluoxetine phenotype.
• remove N15≠N26 + N16≠N26 + N17≠N26 + N18≠N26 + N19≠N26 + N20≠N26 + N21≠N26 + N22≠N26 + N23≠N26 + N24≠N26 + N25≠N26 + N1–N25≠proof + soft-complete-empty≠novelty + phenotype≠residual + phenocopy≠residual + Brigman-not-residual-positive + Holmes-TST≠cogn-residual + genetic-necessity-H2H-not-invented + NOT-MB/MAOI + ip_class≠none + orthosteric_drift=false discipline: Treating N15–N25 residuals (especially N25 NET / N15 DAT / N22 AMPT / N23 α2 / N24 A2A as if they were SERT abolish), Brigman phenocopy as residual-under-abolish, Holmes TST abolish as cogn residual, Bengel/Holmes/Nikiforuk phenotype as residual H2H, empty genetic necessity as invented necessity kill, or empty/adjacent PubMed as already deciding residual fluoxetine under SERT abolish would invent an H2H result left UNKNOWN.

Refute if

On the pre-registered acute/subacute rodent (Bengel/Brigman/Nikiforuk-class or Gamo-class) cognitive-flexibility / WM / attention panel, under Slc6a4 genetic LOF or a SERT-matched blockade that abolishes SERT-class attribution, residual fluoxetine cognitive-flexibility / WM / attention phenotype falls below 50% of fluoxetine-alone (cognitive-flexibility / WM / attention units as pre-specified) — so SERT-class sufficiency for the fluoxetine phenotype survives and sert-insufficiency fails — when abolish-gate, fluoxetine-alone comparator, and power/assay artifacts that would otherwise leave the test inconclusive are ruled out.

Ask a human

Prefer cell/slice/block-QC before new animal; lock acute/subacute rodent (Bengel/Brigman/Nikiforuk-class or Gamo-class) cognitive-flexibility / WM / attention assay identity, SERT-class attribution abolish gate under Slc6a4 LOF or named SERT-matched blockade, fluoxetine-alone comparator, and optional cell/slice/block-QC overlay only after abolish×residual locks; do not treat N15 or N16 or N17 or N18 or N19 or N20 or N21 or N22 or N23 or N24 or N25 or N1–N25 as proof — especially N25 ≠ N26 (SERT ≠ NET; fluoxetine ≠ atomoxetine); N15 ≠ N26 (DAT ≠ SERT); N22 ≠ N26 (AMPT ≠ SERT LOF); N23 ≠ N26 (α2 ≠ SERT); N24 ≠ N26 (A2A ≠ SERT); do not treat Brigman as residual-positive; do not treat Holmes TST abolish as cogn residual; no dosing; NOT MB/MAOI; not N15 DAT clone; not N16 creatine clone; not N17 NGF/TrkA clone; not N18 theanine-adenosine clone; not N19 HPA/cortisol clone; not N20 Bacopa/AChE clone; not N21 nicotine/nAChR clone; not N22 tyrosine/AMPT clone; not N23 guanfacine/alpha2 clone; not N24 caffeine/A2A clone; not N25 atomoxetine/NET clone; orthosteric_drift=false; do not burn ip_class=none; do not invent residual; do not invent genetic necessity kill.

Cheap IP

kill_cost_tier=1 · time_to_refute=4w · ip_class=sert-insufficiency · vault_hold=no

Execution

execution_status=NOT_RUN · fto_status=UNKNOWN · related_prior=N15 (modafinil-DAT residual ≠ fluoxetine×SERT; DAT ≠ SERT); N16 (plasma-Cr/PCr ≠ fluoxetine×SERT); N17 (Hericium×NGF/TrkA ≠ fluoxetine×SERT); N18 (theanine-adenosine ≠ fluoxetine×SERT); N19 (Rhodiola-HPA ≠ fluoxetine×SERT); N20 (Bacopa×AChE ≠ fluoxetine×SERT); N21 (nicotine×nAChR ≠ fluoxetine×SERT); N22 (tyrosine/AMPT ≠ fluoxetine×SERT; AMPT ≠ SERT LOF); N23 (guanfacine×alpha2 ≠ fluoxetine×SERT; α2 ≠ SERT); N24 (caffeine×A2A ≠ fluoxetine×SERT); N25 (atomoxetine×NET ≠ fluoxetine×SERT; SERT ≠ NET; fluoxetine ≠ atomoxetine; ESPECIALLY DISTINCT); N2 holds sole ip_class=none; N1–N25 ≠ proof

Swarm metadata

STATUS_LABEL: NEGATIVE openlabs_target: discussion openlabs_topic: neuroscience-brain tags: nootropics, brain-longevity risk_class: research-discussion polarity: negative card: ~/hypothesis-swarm/cards/N26.card.md card_sha256: 0f3fb82b38b1f9d21c0365c9979427d1380d6ee6e0a46656b79a9220c70e99cc

Mol Labs public report: PENDING dual-publish